127356-16-5

Basic information

• Product Name: 2,3-Pyridinediamine,4-methoxy-(9CI)
• Synonyms: 2,3-Pyridinediamine,4-methoxy-(9CI);2,3-Diamino-4-methoxypyridine;4-methoxypyridine-2,3-diamine
• CAS NO: 127356-16-5
• Molecular Formula: C₆H₉N₃O
• Molecular Weight: 139.16
• Product Categories: PYRIDINE
• Mol File: 127356-16-5.mol

Chemical Properties

• Boiling Point: 335.1±37.0 °C(Predicted)
• Appearance: /
• Density: 1.251±0.06 g/cm3(Predicted)
• PKA: 7.76±0.47(Predicted)
• CAS DataBase Reference: 2,3-Pyridinediamine,4-methoxy-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Pyridinediamine,4-methoxy-(9CI)(127356-16-5)
• EPA Substance Registry System: 2,3-Pyridinediamine,4-methoxy-(9CI)(127356-16-5)

Safety Data

• Hazardous Substances Data: 127356-16-5(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 33, p. 2231, 1990 DOI: 10.1021/jm00170a030

Upstream product

• 84487-08-1 4-methoxy-3-nitro-pyridin-2-ylamine 
• 6980-08-1 4-chloro-3-nitro-2-pyridinamine 
• 19798-80-2 2-Amino-4-chloropyridine 
• 1072-97-5 5-bromo-2-pyridylamine 
• 84249-02-5 2-nitroamino-4-bromopyridine 
• 84487-10-5 2-amino-4-bromo-3-nitropyridine 

Downstream Products

• 127356-20-1 7-Methoxy-2-(2-methoxy-4-methylsulfanyl-phenyl)-1H-imidazo[4,5-b]pyridine 
• 127356-03-0 2-(4-Methanesulfinyl-2-methoxy-phenyl)-7-methoxy-1H-imidazo[4,5-b]pyridine 
• 1426833-17-1 1-(2-chloro-phenyl)-6-methoxy-4-methyl-2,3,5,9,9b-pentaazacyclopenta[a]naphthalene 
• 1426824-69-2 N-[1-(2-chloro-phenyl)-methylidene]-N'-(8-methoxy-2-methyl-pyrido[2,3-b]pyrazin-3-yl)-hydrazine 
• 1426833-18-2 1-(2-chloro-6-methyl-phenyl)-6-methoxy-4-methyl-2,3,5,9,9b-pentaazacyclopenta[a]naphthalene 
• 1426833-19-3 1-(2,6-bismethyl-phenyl)-6-methoxy-4-methyl-2,3,5,9,9b-pentaazacyclopenta[a]naphthalene 

Relevant articles and documents

Polycyclic compound for inhibiting RNA helicase DHX33

The invention relates to a polycyclic compound for inhibiting RNA helicase DHX33. In particular, the invention relates to a compound shown as a formula I or a pharmaceutically acceptable form thereof, a pharmaceutical composition containing the compound, a preparation method of the compound, and medical application of the compound to prevention and/or treatment of DHX33 related diseases.

SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

A model D - amino acid oxidase inhibitor and its preparation and application

The invention provides a novel D- amino acid oxidase inhibitor and a preparation and application thereof. In particular, the invention discloses derivatives of quinoxaline-2,3-diketone, which has a novel structure shown in formula A, as well as a preparation method thereof and an application as an inhibitor of D-amino acid oxidase (DAAO). The compound provided by the invention shows excellent effects of analgesia and blocking morphine analgesia tolerance, and has application value for analgesia, treating opiate drug tolerance, and anti-schizophrenia.

2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE

Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR4; A2 is selected from:, a C5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are β to one another; L1 is selected from: (i)A1-O-CH2-A2; (ii)A1-CH2-O-A2; (iii)A1-C(=O)-NH-A2; (iv)A1-CH(OH)-A2; (v)A1-CH2-NH-C(=O)-A2; (vi) A1-S-CH2-A2; (vii)A1- CH2-S-A2; (viii)A1-CH2-A2; and (ix)A1-CH(CH3)-O-A2; A1 is phenyl, optionally substituted by F or CF3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.

PYRIDINE COMPOUNDS AND USES THEREOF

The present invention is directed to pyridine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psych

Diaminopyridine compounds and methods of use

The present invention relates to compositions and method for inhibiting nonenzymatic cross-linking (protein aging) which contain diaminopyridines and derivates thereof. Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Inotropic 'A' ring substituted sulmazole and isomazole analogues

A series of 'A' ring substituted sulmazole and isomazole analogues have been prepared and evaluated as inotropic agents. pK(A)'s, protonation sites, and log P values were measured for selected compounds and their electronic properties were calculated. No simple correlation between inotropic activity and pK(A), protonation site, or log P value was observed. However, in vitro inotropism did correlate with the calculated charge density of the 'B' ring imidazo nitrogen atom. The 6-position of sulmazole appeared to be the most tolerant toward substituents, th 6-amino derivative 7 being a more potent inotrope than sulmazole itself. 4-Methoxyisomazole 13 had comparable in vivo inotropic properties to those of isomazole.